Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases or critically ill patients worldwide. The company offers heart valve therapy products, including tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve; and produces pericardial and porcine valves from biologically inert animal tissue sewn onto proprietary wire form stents. It also provides critical care products comprising hemodynamic monitoring systems to measure a patient’s heart function in surgical and intensive care settings; Swan-Ganz line of pulmonary artery catheters and PreSep continuous venous oximetry catheters for measuring central venous oxygen saturation; PediaSat oximetry catheters for children; VolumeView sensor-catheters; and FloTrac continuous cardiac output monitoring system, a minimally invasive cardiac monitoring technology for goal-directed fluid optimization. In addition, the company offers cardiac surgery system products, such as ThruPort minimal incision valve surgery platform that enables surgeons to perform intricate procedures through small incisions and tailor procedures; cannulae, which are used during cardiac surgery in venous drainage, aortic perfusion, venting, and cardioplegia delivery; embolic protection devices; and minimally invasive surgery products. Further, it manufactures and sells various vascular products consisting of balloon-tipped, catheter-based embolectomy products, and surgical clips and clamps to treat endolumenal occlusive disease. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

Key Statistics